NCT07911774Completed
Edge AI Neurostimulation Controllers Versus Continuous Therapy for Drug-Resistant Focal Epilepsy
Edge Computing Artificial Intelligence Neurostimulation Controllers Versus Standard Continuous Therapy for Drug Resistant Focal Epilepsy: A Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 3 Nov 2026
Brief summary (registry, in English)
Drug-resistant focal epilepsy remains a major therapeutic challenge. Conventional neurostimulators rely on static, continuous open-loop stimulation or low-bandwidth reactive loops that suffer from classification latency or high battery consumption. This prospective, double-blind, randomized controlled trial evaluates whether hardware-integrated edge computing artificial intelligence (AI) neurostimulators demonstrate superior seizure reduction, lower processing latency, and reduced battery drain compared to standard continuous neurostimulation therapy over a 6-week intervention period.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 80 (actual)
- First submitted
- 28 Oct 2026
- Start date
- 1 Jun 2023
- Primary completion date
- 1 Jan 2024
- Lead sponsor
- Lahore Medical and Dental College
- Diseases
- Epilepsy
- NCT number
- NCT07911774
What you commit to
- Study type: Interventional
- Participants enrolled: 80
- From 1 Jun 2023 to the primary completion date, 1 Jan 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous cranial neurostimulation implants.
- Medical contraindications to surgical implantation or continuous intracortical telemetry.
Other illness
- Diagnosis of primary generalized epilepsy.
- Progressive neurological disorders.
- Severe cognitive impairment.
- Active psychiatric conditions.
Who the study is looking for
- Diagnosed with refractory (drug-resistant) focal epilepsy.
- Minimum of four electroclinically documented disabling focal seizures per month despite compliance with two or more appropriately chosen antiseizure medications.
- Scheduled for clinical intracranial lead implantation (subdural grid or depth electrodes).
- Aged 18 to 65 years at the time of enrollment.
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tertiary Neurosurgical Referral Hospitals Coordinator of this site? Confirm its status | Lahore | Pakistan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.